Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Phyllis F. Cheung

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0075-5679; OpenAlex author ID A5057812298. Sources: OpenAlex.

Their work

Papers
15
Trials
0
Grants
0
Labs led
0
Collaborators
83
Papers, trials and grants by year

2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 15

  1. Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-69013-y↗
  2. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. Co-author DOI 10.1002/1878-0261.13747↗
  3. Transcription factor switching drives subtype-specific pancreatic cancer. Co-author DOI 10.1038/s41588-025-02389-7↗
  4. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. Co-author DOI 10.1186/s12943-025-02406-7↗
  5. Differential activity of MAPK signalling defines fibroblast subtypes in pancreatic cancer. Co-author DOI 10.1038/s41467-024-54975-8↗
  6. Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1021/acs.molpharmaceut.3c00453↗
  7. Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription. Co-author DOI 10.1126/sciadv.adg5109↗
  8. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
  9. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40170-022-00298-5↗
  10. Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2021.07.23.452145↗
  11. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33137↗
  12. MAP Kinase inhibition reshapes tumor microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages Co-author DOI 10.1101/759779↗
  13. A Novel Approach for Image-Guided 131I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene Delivery. Co-author DOI 10.1158/1541-7786.mcr-18-0185↗
  14. Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting. Co-author DOI 10.1158/0008-5472.can-18-0052↗
  15. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends. Co-author DOI 10.1159/000488917↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jens Thomas Siveke · 15 shared papers, 2018–2026 · strength 1.96
  2. Marija Trajkovic‐Arsic · 8 shared papers, 2018–2026 · strength 1.01
  3. Smiths Lueong · 5 shared papers, 2021–2025 · strength 0.63
  4. Andrea Tannapfel · 4 shared papers, 2021–2025 · strength 0.52
  5. Sven‐Thorsten Liffers · 4 shared papers, 2018–2026 · strength 0.46
  6. Erik H.J.G. Aarntzen · 4 shared papers, 2021–2023 · strength 0.46
  7. E. Smeets · 4 shared papers, 2021–2023 · strength 0.46
  8. Rui Fang · 3 shared papers, 2022–2025 · strength 0.45
  9. Rita Teresa Lawlor · 3 shared papers, 2019–2026 · strength 0.43
  10. Aldo Scarpa · 3 shared papers, 2019–2026 · strength 0.43
  11. Stephan A. Hahn · 4 shared papers, 2020–2023 · strength 0.42
  12. Laura Godfrey · 3 shared papers, 2021–2026 · strength 0.40
  13. Rickmer Braren · 3 shared papers, 2021–2026 · strength 0.40
  14. Jörg D. Hoheisel · 3 shared papers, 2021–2025 · strength 0.40
  15. Barbara T. Grünwald · 2 shared papers, 2025–2026 · strength 0.37
  16. Niklas Krebs · 2 shared papers, 2025–2026 · strength 0.37
  17. Diana Behrens · 2 shared papers, 2024–2026 · strength 0.36
  18. Manfred Paul Lutz · 2 shared papers, 2018–2025 · strength 0.33
  19. Francesca Lupo · 2 shared papers, 2019–2024 · strength 0.23
  20. Vincenzo Corbo · 2 shared papers, 2019–2024 · strength 0.23
  21. Pietro Delfino · 2 shared papers, 2019–2024 · strength 0.23
  22. Sabrina L. D’Agosto · 2 shared papers, 2019–2024 · strength 0.23
  23. Elena Fiorini · 2 shared papers, 2019–2024 · strength 0.23
  24. Juanfei Peng · 1 shared paper, 2026 · strength 0.20
  25. Markus Vogt · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.